GR2301
/ Zhixiang (Shanghai) Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 25, 2025
A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.
(clinicaltrials.gov)
- P1 | N=36 | Not yet recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
New P1 trial
1 to 1
Of
1
Go to page
1